Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645522 | 0.85 | OPRM1 (0.40) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL30291243 | 0.85 | OPRM1 (0.40) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL23645212 | 0.83 | OPRM1 (0.33) | OPRM1OPRL1DPP4SIGMAR1 | |
| SCHEMBL23645211 | 0.83 | OPRM1 (0.35) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL30291320 | 0.81 | OPRM1 (0.41) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL23668800 | 0.81 | OPRM1 (0.41) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL23645286 | 0.77 | OPRM1 (0.35) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL23645063 | 0.75 | OPRM1 (0.38) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL23645508 | 0.74 | SIGMAR1 (0.39) | OPRM1OPRL1DPP4SIGMAR1HDAC4 | |
| SCHEMBL30291301 | 0.74 | SIGMAR1 (0.39) | OPRM1OPRL1DPP4SIGMAR1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087700-B | Spirocyclic tetrahydroquinazolines | 苏州亚盛药业有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021139748-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230174-A1 | SPIROCYCLIC TETRAHYDROQUINAZOLINES | KRAS, NRAS, HRAS | OPRM1 2886/4885OPRL1 2634/4885DPP4 3662/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | OPRM1 2886/4885OPRL1 2634/4885DPP4 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.